Jazz Pharmaceuticals Acquires SpringWorks' FAAH Inhibitor Program for Post-Traumatic Stress Disorder
Shots:
- SpringWorks to receive $35M as upfront and $ 375M as clinical- regulatory- and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to get an exclusive license of all assets relating to the FAAH inhibitor program including PF-04457845
- The acquisition magnifies Jazz's neuroscience pipeline into a new disease area- further optimizes SpringWorks' strategic focus on targeted oncology
- Jazz will initially focus on developing PF-04457845 as a treatment in PTSD for patients with inadequate response to currently approved therapies
Ref: PRNewswire | Image: Spring Works
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com